Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cytochrome P450 family 2 subfamily C member 61, pseudogene (CYP2C61P), is classified as a pseudogene within the cytochrome P450 gene family in humans. Unlike functional cytochrome P450 enzymes, CYP2C61P does not code for an active protein and has no direct enzymatic or signaling role in metabolism. While most pseudogenes are biologically inactive, a minority can exert regulatory effects via RNA transcripts, but there is no evidence for such activity for CYP2C61P. It is not involved in drug metabolism, disease pathways, or used in clinical practice, and should not be considered a therapeutic target. The confusion likely arises from its naming similarity to other cytochrome P450 enzymes, many of which are important drug targets and mediate essential metabolic functions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cytochrome P450 family 2 subfamily C member 61, pseudogene (CYP2C61P).